Sigma Healthcare Ltd (ASX: SIG) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Sigma Healthcare Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $33.48 billion
P/E Ratio 56.67
Dividend Yield 0.45%
Shares Outstanding 11.50 billion
Earnings per share -0.009
Dividend per share 0.03
Year To Date Return -1.70%
Earnings Yield 1.76%
Franking 100%
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Sigma Healthcare Ltd (ASX: SIG)
    Latest News

    A group of people in a corporate setting do a collective high five.
    Healthcare Shares

    3 quality ASX healthcare shares worth buying now

    Brokers think the tide is turning for these battling medical heavyweights.

    Read more »

    A woman stands at her desk looking a her phone with a panoramic view of the harbour bridge in the windows behind her with work colleagues in the background.
    Investing Strategies

    The 3 stocks I'd buy and hold into 2026

    I am looking for ASX stocks that can compound steadily and remain relevant through 2026 and beyond.

    Read more »

    A smiling woman holds her hands up in front of an orange background.
    Investing Strategies

    Here are my top 10 ASX stocks for 2026

    For 2026, I’m focused on ASX stocks with strong fundamentals, proven management, and the ability to compound through volatility.

    Read more »

    A woman wearing dark clothing and sporting a few tattoos and piercings holds a phone and a takeaway coffee cup as she strolls under the Sydney Harbour Bridge which looms in the background.
    Investing Strategies

    5 unbeatable ASX stocks I'm eager to buy in 2026

    As 2026 begins, these five ASX stocks are the ones I am most eager to buy for long-term growth.

    Read more »

    Excited group of friends sitting on sofa watching sports on TV and celebrating.
    Investing Strategies

    My top 5 ASX stocks to buy in early 2026

    As conditions improve in early 2026, these five ASX stocks could be well placed for the next stage of the…

    Read more »

    A panel of four judges hold up cards all showing the perfect score of ten out of ten
    Opinions

    The best ASX 200 stocks to own in 2026

    Not all ASX 200 stocks are built for the long haul.

    Read more »

    Stethoscope with a piggy bank and hundred dollar notes.
    Healthcare Shares

    Here's the dividend forecast out to 2030 for Sigma shares

    This business could pay healthy dividends in the coming years…

    Read more »

    Seven people look for bargains to buy at a yard sale.
    Consumer Staples & Discretionary Shares

    Macquarie names its top ASX consumer staples and consumer discretionary stock picks

    Do you have exposure to these stocks in your portfolio?

    Read more »

    Winning woman smiles and holds big cup while losing woman looks unhappy with small cup
    Share Gainers

    Here are the top 10 ASX 200 shares today

    It was a dour Tuesday for ASX investors.

    Read more »

    A man in a business suit scratches his head looking at a graph that started high then dips, then starts to go up again like a rollercoaster.
    Healthcare Shares

    Is Sigma Healthcare share a healthy buy, after hitting new lows?

    The Chemist Warehouse merger and ageing population might boost this stock's appeal.

    Read more »

    A senior pharmacist talks to a customer at the counter in a shop.
    Healthcare Shares

    Should I buy Sigma Healthcare shares for the Chemist Warehouse exposure?

    Is this ASX stock a healthy buying opportunity?

    Read more »

    Young man with a laptop in hand watching stocks and trends on a digital chart.
    Broker Notes

    Buy, hold, sell: Sigma Healthcare, CSL, and Lynas shares

    Analysts have given their verdict on these shares.

    Read more »

    Dividend Payment History Data provided by Morningstar.

    Data provided by Morningstar.
    Ex-Date Amount Franking Type Payable
    02 Sep 2025 $0.0130 100.00% Interim 18 Sep 2025
    01 Oct 2024 $0.0050 0.00% Interim 17 Oct 2024
    28 Mar 2024 $0.0050 50.00% Final 17 Apr 2024
    25 Sep 2023 $0.0050 100.00% Interim 11 Oct 2023
    30 Mar 2023 $0.0050 100.00% Final 18 Apr 2023
    29 Sep 2022 $0.0050 100.00% Interim 12 Oct 2022
    04 Apr 2022 $0.0100 100.00% Final 22 Apr 2022
    24 Sep 2021 $0.0100 100.00% Interim 08 Oct 2021
    06 Apr 2021 $0.0100 100.00% Final 21 Apr 2021
    19 Sep 2019 $0.0100 100.00% Interim 04 Oct 2019
    03 Apr 2019 $0.0200 100.00% Final 29 Apr 2019
    12 Oct 2018 $0.0150 100.00% Interim 29 Oct 2018
    05 Apr 2018 $0.0250 100.00% Final 20 Apr 2018
    19 Sep 2017 $0.0250 100.00% Interim 05 Oct 2017
    06 Apr 2017 $0.0300 100.00% Final 21 Apr 2017
    20 Sep 2016 $0.0250 100.00% Interim 03 Oct 2016
    06 Apr 2016 $0.0300 100.00% Final 21 Apr 2016
    03 Apr 2014 $0.0200 100.00% Final 30 Apr 2014
    21 Sep 2012 $0.0200 100.00% Interim 26 Oct 2012
    05 Apr 2011 $0.1500 100.00% Special Cash 11 May 2011
    16 Oct 2009 $0.0300 100.00% Interim 13 Nov 2009
    31 Mar 2009 $0.0400 100.00% Final 07 May 2009
    30 Sep 2008 $0.0300 100.00% Interim 29 Oct 2008
    29 Aug 2005 $0.0200 100.00% Interim 15 Sep 2005
    02 Mar 2004 $0.2000 100.00% Final 23 Mar 2004

    SIG ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Sigma Healthcare Ltd

    Sigma Healthcare Ltd. engages in the manufacture and distribution of pharmaceutical products through pharmacy, grocery channels, and private label. The firm operates through the Amcal, Guardian, PharmaSave, Chemist King, and Discount Drug Stores retail brands. It also involves in the provision of services to retail pharmacists in Australia. The company was founded on July 2, 1999 and is headquartered in Rowville, Australia.

    SIG Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    13 Jan 2026 $2.90 $-0.02 -0.68% 5,018,451 $2.92 $2.94 $2.89
    12 Jan 2026 $2.92 $0.03 1.04% 8,962,925 $2.89 $2.92 $2.87
    09 Jan 2026 $2.89 $0.01 0.35% 6,468,939 $2.90 $2.91 $2.88
    08 Jan 2026 $2.88 $0.02 0.70% 7,435,624 $2.90 $2.91 $2.85
    07 Jan 2026 $2.86 $0.03 1.06% 8,352,951 $2.83 $2.88 $2.83
    06 Jan 2026 $2.83 $-0.09 -3.08% 14,555,700 $2.92 $2.93 $2.82
    05 Jan 2026 $2.92 $-0.02 -0.68% 5,834,687 $2.94 $2.95 $2.91
    02 Jan 2026 $2.94 $0.00 0.00% 3,411,839 $2.94 $2.96 $2.92
    31 Dec 2025 $2.94 $-0.03 -1.01% 6,978,731 $2.95 $2.98 $2.93
    30 Dec 2025 $2.97 $0.01 0.34% 3,529,742 $2.98 $2.99 $2.96
    29 Dec 2025 $2.96 $-0.02 -0.67% 3,826,152 $2.98 $2.99 $2.95
    24 Dec 2025 $2.98 $0.01 0.34% 4,129,282 $2.96 $2.98 $2.95
    23 Dec 2025 $2.97 $0.02 0.68% 6,651,432 $2.94 $2.97 $2.92
    22 Dec 2025 $2.95 $-0.05 -1.67% 8,599,402 $3.00 $3.03 $2.94
    19 Dec 2025 $3.00 $0.10 3.45% 26,453,981 $2.97 $3.02 $2.95
    18 Dec 2025 $2.90 $-0.04 -1.36% 13,663,019 $2.91 $2.93 $2.89
    17 Dec 2025 $2.94 $-0.02 -0.68% 11,713,134 $2.98 $2.98 $2.94
    16 Dec 2025 $2.96 $0.05 1.72% 15,863,796 $2.90 $2.99 $2.90

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    10 Nov 2025 Annette Carey Buy 10,000 $31,237
    On-market trade.
    28 Aug 2025 Jack Gance Sell 155,103,420 $480,820,602
    Off-market trade.
    29 May 2025 Danielle Di Pilla Sell 7,342,150 $23,312,794
    On-market trade.
    28 May 2025 Danielle Di Pilla Sell 7,500,000 $24,000,000
    On-market trade.
    27 May 2025 Danielle Di Pilla Sell 14,764,652 $46,609,053
    On-market trade.
    26 May 2025 Danielle Di Pilla Sell 235,348 $741,346
    On-market trade.
    09 May 2025 Damien Gance Sell 126,500,000 $382,030,000
    Off-market trade.
    14 Apr 2025 Damien Gance Sell 100,000,000 $297,000,000
    Off-market trade.
    14 Feb 2025 Damien Gance Sell 40,000,000 $120,000,000
    Off-market trade.
    14 Feb 2025 Vikesh Ramsunder Exercise 1,965,878 $6,133,539
    Conversion of securities. 1,010,723 - Rights
    14 Feb 2025 Vikesh Ramsunder Buy 1,965,878 $6,133,539
    Conversion of securities.
    13 Feb 2025 Vikesh Ramsunder Sell 11,662,028 $34,053,121
    On-market trade. Average Price
    12 Feb 2025 Vikesh Ramsunder Exercise 1,167,106 $3,221,212
    Conversion of securities. 4,921,778 - Rights
    12 Feb 2025 Vikesh Ramsunder Expiry 1,945,177 $5,368,688
    As advised by the company. 2,976,601 - Rights
    lapse of remaining 1,945,177 EEG Rights
    12 Feb 2025 Vikesh Ramsunder Buy 1,167,106 $3,221,212
    Conversion of securities.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Dr Christopher Graham Roberts Non-Executive Director Oct 2023
    Dr Roberts has more than 40 years of experience in the medical device industry, including as the former Chief Executive Officer of Cochlear Limited from 2004 to 2015, Executive Vice President of ResMed Inc (NYSE:RMD) from 1992 to 2003 and as a director of ResMed Inc until November 2017. He is currently a non-executive director of HMC Capital Ltd (ASX:HMC). HMC Capital managed HealthcCo Healthcare and Wellness REIT (ASX:HCW), HMC Capital Partners Fund 1, Clarity Pharmaceuticals Limited (ASX:CU6), Nutromics Pty Ltd, Atmo Biosciences Limited and the Cochlear Foundation Board. He is also a Governor of the Centenary Institute Cancer Medicine and Cell Biology.
    Mr Neville Mitchell Non-Executive Director Feb 2023
    Mr Mitchell has international healthcare and finance experience. He was Chief Financial Officer and Company Secretary at ASX-listed Cochlear Limited, a world leading medical device developer, manufacturer and seller of hearing devices. Mr Mitchell is currently the Chairman of ASX and NZX-listed Fisher&Paykel Healthcare Corporation (non-executive director from November 2018) and a non-executive director of Sonic Healthcare Limited from September 2017. He is Chair of the Sonic Audit Committee. He was formerly a non-executive director of ASX-listed Sirtex Healthcare, Osprey Medical Inc and Q'Biotics Group Limited. He has also performed roles with several industry and Government committees.
    Mr Michael Sammells Non-Executive DirectorNon-Executive Chairman Feb 2020
    Mr Sammells is also currently a non-executive director at AMP Limited and a director at GMBHA. He has 35 years of broad experience in finance, corporate services and has held operational roles with expertise in finance, accounting, treasury, investor relations, capital development, mergers and acquisitions and IPOs. Further, Mr Sammells is a former Chief Financial Officer of Healthscope Limited and Medibank Private.
    Mr Vikesh Ramsunder Chief Executive OfficerManaging Director Feb 2022
    Mr Ramsunder has experience in pharmacy retailing, wholesaling and logistics. He spent 28 years with the Clicks Group in South Africa. This included 18 years as part of the executive team. Before becoming Clicks Group Chief Executive Officer in January 2019, Mr Ramsunder held several roles within Clicks, including Chief Operating Officer from 2015 and Managing Director of the pharmaceutical wholesale business, United Pharmaceutical Distributors from 2010.
    Ms Annette May Carey Non-Executive Director Apr 2023
    Ms Carey is a current non-executive director of National Intermodal Corporation and a non-executive director of the Kinetic bus group. Prior to joining Sigma, Ms Carey has held director roles within the Linfox group of companies and has been Chair or Deputy Chair of Australia Post joint ventures in the UK and China. She has previously held various senior roles within the Linfox Logistics group, progressing from General Counsel and Company Secretary to Chief Executive Officer. Ms Carey also held the position of Executive General Manager International with Australia Post. Ms Carey is a member of Chief Executive Women.
    Mr Jack Gance Non-Executive Director Feb 2025
    Mr D Gance is a qualified pharmacist who joined MyChemist in 1998 and is currently the Chief Commercial Officer of Chemist Warehouse. Mr D Gance was the first Chemist Warehouse Franchisee opening the first Chemist Warehouse pharmacy in June 2000.
    Ms Danielle Di Pilla Executive Director Feb 2025
    Ms Di Pilla is a qualified pharmacist who is currently the Chief People Officer at Chemist Warehouse. Ms Di Pilla established DPP Pharmaceuticals Pty Ltd (DPP) in 2000 and is the founder of brands such as Goat Soap, which has had international success. Ms Di Pilla has been the managing director of DPP since it was incorporated. DPP is a wholly owned subsidiary of Chemist Warehouse. Ms Di Pilla also sits on the Board of Gotcha4Life.
    Mr Mario Verrocchi Executive Director Feb 2025
    Mr Verrocchi joined Jack and Sam Gance's pharmacy group in 1982. Mr Verrocchi established MyChemist with Jack Gance and Sam Gance in 1997 and subsequently created the Chemist Warehouse chain with Messrs Gance in 2000. He is currently Chief Executive Officer of Chemist Warehouse.
    Mr Damien Gance Executive Director Feb 2025
    Mr J Gance as a pharmacist in 1967 and opened his first pharmacy store in Reservoir, Victoria, with Sam in 1972. In 1997, Mr J Gance, Sam Gance and Mario Verrocchi, established MyChemist and opened the first MyChemist store. In 2000, Mr J Gance, along with Mr Sam Gance and Mr Verrocchi, established the Chemist Warehouse chain and opened the first Chemist Warehouse store. Mr J Gance also created the brands Le Specs, Le Tan and Colours of Australis.
    Ms Kara McGowan General CounselCompany Secretary Oct 2021
    -
    Kara McGowan General CounselCompany Secretary
    -
    Mr M Conway Chief Financial Officer
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    HSBC Custody Nominees (Australia) Limited 871,241,938 14.61%
    Citicorp Nominees Pty Limited 445,477,631 7.47%
    J P Morgan Nominees Australia Pty Limited 359,556,170 6.03%
    Dgsr Family Foundation Pty Ltd 353,829,615 5.93%
    Av Family Foundation Pty Ltd 313,784,873 5.26%
    Mjv Family Foundation Pty Ltd 313,784,873 5.26%
    Mr Sunil Narula 165,893,114 2.78%
    Bond Street Custodians Limited 150,545,209 2.52%
    Mat Family Foundation Pty Ltd 148,144,781 2.48%
    HMC Capital Partners Holdings Pty Ltd 103,399,008 1.73%
    Ms Nancy Fei Fei Jian 86,118,340 1.44%
    HSBC Custody Nominees (Australia) Limited Gsco Eca 75,333,468 1.26%
    Mr Azman Rashid Haroon 64,502,845 1.08%
    Ms Danielle Di Pilla 61,243,218 1.03%
    Mr Claudio Avendano 55,986,398 0.94%
    Citicorp Nominees Pty Limited i 51,603,737 0.87%
    Bond Street Custodians Limited i 48,455,727 0.81%
    Di Pilla Investments Pty Ltd 44,228,054 0.74%
    Mr William Ho 41,669,145 0.70%
    Bond Street Custodians Limited ii 41,505,949 0.73%
    Mr Anthony Paul Bassaly 39,768,975 0.67%

    Profile

    since

    Note